TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34424995
Drug: Crystalloid-based priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid-based priming solution (Ringer-Acetate plus mannitol)
Study: 33854007
Drug: UIC201609/UIC201610 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: UIC201609/UIC201610 (combination of rabeprazole and CR mosapride)
Study: 33854007
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg once a day
Study: 33854007
Drug: mosapride 15
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mosapride 15 mg CR tablet once a day
Study: 34928306
Drug: Erenumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (both doses)
Study: 33463426
Drug: Epinephrine (EPN)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EPN) irrigation solution (0.33 mg per 1 L of saline)
Study: 33463426
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) irrigation solution (0.42 mg per 1 L of saline)
Study: 33153578
Drug: LDL-C <70
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C <70 mg/dl
Study: 34903035
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation (RDN) therapy
Study: 32191001
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium suppositories
Study: 35255859
Drug: Sexual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual and Reproductive Health (SRH): Baseline self-collected vaginal and urine samples with study-organized clinic appointments for results, treatment and delivery of HIV testing, ART and PrEP integrated with SRH services
Study: 35255859
Drug: SRH +
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRH + peer-support: Combination of SRH services and peer navigator support
Study: 36031597
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light therapy
Study: 35491787
Drug: Sham light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham light therapy
Study: 35999562
Drug: Berberine and
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine and fenugreek co-supplementation (3 capsules/day of 500 mg: 300 mg of berberine + 200 mg of fenugreek seed powder) for 12 weeks
Study: 34712203
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea polyphenols (DGTP) 400 mg/day for 12 weeks
Study: 33553662
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention by clinical pharmacists including training on IBS-related knowledge, medication adherence, lifestyle, and diet adjustments.
Study: 33553662
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (nonintervention group).
Study: 33037036
Drug: Exenatide two
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg for 28 weeks)
Study: 33037036
Drug: Exenatide QWS-AI
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QWS-AI (2 mg) continued for 52 weeks
Study: 35143603
Drug: Intra-arterial alteplase
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes
Study: 33606922
Drug: GSK3352589 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3352589 single-dose (2 to 400 mg, including 25 mg food effect arm)
Study: 33606922
Drug: GSK3352589 repeat-dose
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3352589 repeat-dose (5 to 200 mg, twice daily for 14 days with food)
Study: 33606922
Drug: GSK3352589 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3352589 (both single and repeat doses)
Study: 32297043
Drug: Urea at
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea at 40 g/kg DM
Study: 32297043
Drug: Urea at
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea at 60 g/kg DM
Study: 32297043
Drug: NaOH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOH at 40 g/kg DM
Study: 32297043
Drug: NaOH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOH at 60 g/kg DM
Study: 32297043
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no chemical treatment)
Study: 35802515
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy for 3 months
Study: 35802515
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy for 3 months (adherent participants)
Study: 34931603
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) treatment
Study: 33461636
Drug: Asenapine 10
Normalized name: asenapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 10 mg/day
Study: 33461636
Drug: Asenapine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 20 mg/day
Study: 34080890
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus Naltrexone (2 mg/day of varenicline plus 50 mg/day of naltrexone)
Study: 34080890
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus Placebo (2 mg/day of varenicline plus matched placebo)
Study: 32783585
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lidocaine/prilocaine (EMLA)
Study: 32783585
Drug: Patch electrode
Normalized name: ELECTRODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch electrode stimulation
Study: 35908601
Drug: Active capacitive-resistive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active capacitive-resistive electrical therapy to the lower cervical region (C4-C7), twice weekly for a total of six treatments
Study: 35908601
Drug: Sham (inactive)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (inactive) treatment
Study: 32389738
Drug: Topical tacalcitol
Normalized name: tacalcitol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacalcitol plus 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Study: 32389738
Drug: 5‐aminolevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT) alone
Study: 33798311
Drug: Cupping treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping treatment combined with antibiotics (cefodizine sodium 80 mg/(kg•d) for 7 days)
Study: 33798311
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (cefodizine sodium 80 mg/(kg•d) for 7 days)
Study: 35248132
Drug: Low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticagrelor combined with 100 mg aspirin
Study: 35248132
Drug: Standard-dose ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ticagrelor combined with 100 mg aspirin
Study: 32194222
Drug: Placebo (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (900 mg of edible paraffin)
Study: 35686998
Drug: Daily cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cannabis use after acute cannabis use
Study: 32560639
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg alone
Study: 32560639
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg with macular laser
Study: 32955601
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 20 ml of 0.25% bupivacaine
Study: 32955601
Drug: Mid-transverse to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-transverse to pleura (MTP) block with 20 ml of 0.25% bupivacaine
Study: 34118712
Drug: StaySafe app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: StaySafe app (12 weekly sessions)
Study: 32654362
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential treatment of sunitinib followed by everolimus
Study: 36419181
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (KET) 0.5 mg/kg over 40 min
Study: 36419181
Drug: IM naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM naltrexone (NTX) 380 mg once
Study: 33205924
Drug: FDS76® dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDS76® dental implant
Study: 32924897
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (BLT)
Study: 33549453
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving a monthly motivational phone call
Study: 37355526
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy (NST)
Study: 35799113
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of medications
Study: 35395069
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily (females subgroup)
Study: 35395069
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily (males subgroup)
Study: 35644071
Drug: Flumazenil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (4 mg/24 h for approximately eight days)
Study: 34116204
Drug: EPCO patients
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPCO patients with different treatment durations
Study: 33768537
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control (treatment as usual).
Study: 32419281
Drug: Isoflavones (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (100 mg daily for 8 weeks)
Study: 32758312
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (PE-A)
Study: 33394814
Drug: Self-reported drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drug use by questionnaires
Study: 33976537
Drug: High-dose lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lidocaine (Group HL: 1.5 mg/kg bolus followed by an infusion at 2.0 mg/kg/hour)
Study: 33976537
Drug: Low-dose lidocaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lidocaine (Group LL: 1.5 mg/kg bolus followed by an infusion at 1.0 mg/kg/hour)
Study: 33976537
Drug: High-dose lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lidocaine (Group HL)
Study: 35982198
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration
Study: 33430927
Drug: Immunosuppression guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression guided by TTV monitoring in addition to conventional therapeutic drug monitoring of tacrolimus trough levels
Study: 33430927
Drug: Conventional therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapeutic drug monitoring
Study: 34260478
Drug: Low-fat, vegan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, vegan diet including ½ cup (86 g) of cooked soybeans daily for 12 weeks
Study: 32077907
Drug: Nonstudy eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstudy eye received DME treatment within 4 months of randomization
Study: 35794673
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1 g 4 times a day
Study: 32402480
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg i.v. haloperidol
Study: 33395437
Drug: COTiD-UK (Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: COTiD-UK (Community Occupational Therapy for people with dementia)
Study: 32252062
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) infusion
Study: 35471655
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) with head-of-bed elevation
Study: 35471655
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) without head-of-bed elevation
Study: 35471655
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (alone or in combination with head-of-bed elevation)
Study: 32127335
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2000 mg docosahexaenoic acid + 400 mg eicosapentaenoic acid/day)
Study: 32977404
Drug: Curcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (160 mg/day)
Study: 33097947
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fish oil and curcumin
Study: 34666139
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug (AAD) therapy
Study: 33079154
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of praliciguat daily for 12 weeks (n=91)
Study: 35795714
Drug: IVIG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (400 mg/kg daily for five consecutive days starting at 4-6 weeks of gestation)
Study: 35795714
Drug: IVIG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (400 mg/kg daily for five consecutive days starting at 4-5 weeks of gestation)
Study: 34270930
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Lactobacillus casei Zhang (L. casei Zhang)
Study: 33196565
Drug: Topical eyedrops
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical eyedrops only (Control)
Study: 33634869
Drug: Pembrolizumab 100
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 100 mg (Pem100)
Study: 33634869
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg (Pem200)
Study: 33634869
Drug: Pembrolizumab 100
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 100 mg (Pem100) with chemotherapy
Study: 33634869
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg (Pem200) with chemotherapy
Study: 33634869
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis for Pembrolizumab 100 mg (Pem100)
Study: 36167573
Drug: Oral co‐trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co‐trimoxazole 960 mg once daily for 18 months
Study: 36167573
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 18 months
Study: 35633124
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (low molecular weight heparin and vitamin K antagonists)
Study: 33472925
Drug: Preconditioned autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconditioned autologous MSC injections
Study: 32828488
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide donors, alpha‐2‐agonists, and calcium channel blockers
Study: 36357795
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide (3 doses of 50 µg/day)
Study: 32921989
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg kg−1 (Group D)
Study: 32921989
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg kg−1 and ketamine 2 mg kg−1 (Group DK)
Study: 32623288
Drug: Panitumumab-based treatment
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-based treatment (induction with panitumumab-FOLFOX followed by maintenance with single-agent panitumumab)
Study: 32623288
Drug: Single-agent panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-agent panitumumab (after 4-month induction with panitumumab-FOLFOX)
Study: 37527856
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (PT)
Study: 33463020
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (PT) or internet-based exercise training (IBET)
Study: 32382926
Drug: Potassium oxalate
Normalized name: POTASSIUM OXALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium oxalate (Oxa‐Gel BF)
Study: 32382926
Drug: Potassium oxalate
Normalized name: POTASSIUM OXALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium oxalate (Oxa‐Gel BF) associated with GaAlAs low‐power laser
Study: 35672866
Drug: Omega-3 fish
Normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fish oil (6.2 g daily)
Study: 32464903
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside, 20 mg/kg
Study: 34148021
Drug: Single antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antihypertensive medication
Study: 34148021
Drug: Multiple antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple antihypertensive medications
Study: 34148021
Drug: Preferred classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred classes of antihypertensive drugs
Study: 34713983
Drug: TT+RT (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT+RT (testosterone treatment + resistance training)
Study: 34713983
Drug: no-TT (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-TT (testosterone treatment only)
Study: 32112166
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine with intravenous analgesia (ITM-IV)
Study: 32112166
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia without intrathecal morphine (IV)
Study: 36166405
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose (10 mg/kg) of liposomal amphotericin B with optimized oral backbone of fluconazole and flucytosine
Study: 36166405
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose (10 mg/kg) of liposomal amphotericin B
Study: 35218356
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of measles vaccine (MV2) at 18 months of age
Study: 35218356
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of measles vaccine (MV2) after OPV campaigns
Study: 35218356
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of measles vaccine (MV2)
Study: 35388309
Drug: Date Palm
Normalized name: date palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date Palm Pollen (DPP) 3 grams twice a day for two months
Study: 36129240
Drug: Sham patch
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham patch
Study: 33225410
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (DMF) 240 mg twice daily
Study: 33184146
Drug: Cholecalciferol 60,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 60,000 IU daily for 7 days
Study: 34803148
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate ointment
Study: 34803148
Drug: Tocopherol acetate
Normalized name: Tocopherol acetate
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol acetate ointment
Study: 32950726
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) on dorsum of tongue
Study: 32950726
Drug: Tongue scrappers
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue scrappers (TS) and adjunctive PDT
Study: 32167679
Drug: Sacubitril–valsartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril–valsartan treatment
Study: 32851572
Drug: Parenteral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral therapy